If you or a loved one has newly diagnosed higher-risk Myelodysplastic Syndrome (MDS), it could be RARA-positive MDS.

Approximately 30% of patients with MDS are RARA-positive. Syros's oral investigational treatment SY-1425 represents the first targeted approach in clinical development for this patient population.

With all enrolled patients receiving either the investigational treatment or the standard of care therapy, this study compares the efficacy of SY-1425 in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.

Trial participant eligibility key criteria:

- 18 years of age and older
- RARA-positive, based on the investigational assay
- Newly diagnosed with very high, high or intermediate risk MDS
- Have not received prior treatment for MDS

Contact your doctor to discuss participation in the SY-1425 trial. For more information about the SY-1425 trial visit ClinicalTrials.gov and search NCT04797780.

SYROS

An expression makes a world of difference

SY-1425 is an investigational agent and has not been approved by the FDA as a treatment for any indication.